Open AccessP766: CLINICAL OUTCOMES IN PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROMES RECEIVING HYPOMETHYLATING AGENTS: A LARGE POPULATION‐BASED ANALYSIS
Author(s) -
Zeidan A. M.,
Mearns E. S.,
Ng C.,
Shah A.,
Lamarre N.,
YellowDuke A.,
Alrawashdh N.,
Yang B.,
Cheng W.,
Bui C. N.,
Svensson A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845948.33476.47
Subject(s) - medicine , decitabine , myelodysplastic syndromes , azacitidine , population , hypomethylating agent , incidence (geometry) , international prognostic scoring system , myeloid leukemia , oncology , pediatrics , bone marrow , gene expression , environmental health , dna methylation , gene , biochemistry , chemistry , physics , optics